ArticleFrontiers in cardiovascular medicine2026
Interpretable machine learning and mendelian randomization identify risk factors for lower extremity arterial embolism and thrombosis.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lower extremity arterial embolism and thrombosis lead to significant morbidity, but their risk factors are not fully characterized. Objectives: To identify risk factors and develop an interpretable machine learning (ML) model for predicting lower extremity arterial embolism and thrombosis, with validation using mendelian randomization (MR). Methods: In this retrospective case-control study, data were collected from patients with lower extremity arterial embolism and thrombosis treated at our department of vascular surgery between January 2018 and November 2025. Predictors were selected using LASSO regression, and 11 ML models were developed using the selected variables. The optimal model was interpreted and implemented as a web-based prediction tool. Clinical utility and model calibration were assessed using decision curve analysis and calibration curves. Key predictors were further assessed using MR and multivariable logistic regression. Results: XGBoost achieved the highest discrimination, with an AUC of 0.951 (95% CI 0.925-0.972) in the test set. MR analyses indicated that genetically predicted cerebrovascular disease (CD) (OR 1.773; 95% CI 1.043-3.015; Conclusions: Interpretable ML combined with MR identified a history of CD and lower MPV as factors associated with risk of lower extremity arterial embolism and thrombosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.